Curaleaf
Curaleaf is a publicly traded, vertically integrated cannabis operator running 165 dispensaries across 14+ U.S. states and EU-GMP certified international medical distribution across Germany, the UK, Poland, Australia, and New Zealand, selling its own brands (Select, Grassroots, Reef) to medical patients, adult-use consumers, and wholesale buyers.
- Company typePublic
- Founded2010
- HeadquartersStamford, United States
- Headcount1,001–5,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What Curaleaf does
Curaleaf Holdings, Inc. is a publicly traded, vertically integrated cannabis operator (CSE: CURA; OTC: CURLF; TSX listed) headquartered in Stamford, Connecticut, with corporate origins tracing to 2010. The company operates the largest U.S. multi-state cannabis retail footprint among MSOs, running 162–165 company-operated and branded dispensaries across 14+ U.S. states — including 73 in Florida alone — alongside vertically integrated cultivation (indoor, outdoor and greenhouse, anchored by Los Sueños Farms, Colorado's largest outdoor grow), EU-GMP and GDP certified processing, and pharmaceutical-grade manufacturing. It sells directly to medical patients and adult-use consumers, distributes wholesale to independent dispensaries under owned brands (Select, Grassroots, Find, Anthem, Reef, Dark Heart, Higher Stitch, Jams, Endless Coast Seltzer), and operates internationally via Four 20 Pharma (Germany, EU-GMP/GDP licensed), Curaleaf Laboratories (UK — including the first UK-licensed manufacturer of medical cannabis suppositories and pessaries), Can4Med (Poland), and Australian/NZ distribution partnerships.
The platform combines low-cost outdoor and indoor cultivation with branded retail and proprietary product technology — most notably Select Briq 2 (a vape with Flavor Protection Technology and Meter Mode Intelligence, launched March 2026) and a water-based THCA extraction process achieving >90% THC clarity (recognized in the 2025 CannaTech Innovation Awards). Distribution reaches U.S. consumers via retail, state-specific e-commerce subdomains subject to shipping restrictions, B2B wholesale, and branded dispensary partnerships with licensed operators (e.g., RC Retail in Ohio). International medical cannabis distribution covers Germany, the UK, Poland, Australia and New Zealand; Q1 2026 international revenue of $47.2M (+35% YoY) reflects accelerating non-U.S. growth.
The revenue model combines direct-to-consumer dispensary sales (transaction-based, unit-priced), wholesale/B2B distribution to third-party dispensaries, and international medical cannabis distribution (managed-services style via EU-GMP supply chain). FY2025 revenue of $1.27B produced $275M adjusted EBITDA (22% margin); Q1 2026 produced $70.1M net income (vs. a $61.1M prior-year loss) following federal rescheduling of medical marijuana from Schedule I to Schedule III in April 2026, which the company estimates unlocks ~$116M in annual Section 280E tax relief. The June 2026 shareholder-approved reincorporation from British Columbia to Delaware, paired with a 1-for-3 reverse stock split, is positioned to support a potential U.S. exchange uplisting.
Curaleaf firmographics
Firmographics- Name
- Curaleaf
- Legal name
- Curaleaf Holdings, Inc.
- Website
- https://curaleaf.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Curaleaf is a publicly traded, vertically integrated cannabis operator running 165 dispensaries across 14+ U.S. states and EU-GMP certified international medical distribution across Germany, the UK, Poland, Australia, and New Zealand, selling its own brands (Select, Grassroots, Reef) to medical patients, adult-use consumers, and wholesale buyers.
- Ownership category
- akta.pro rank
Curaleaf industry classification
Industry- Product category
- Cannabis Products
- NAICS
- Beer, Wine, and Liquor Retailers (445320)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industries
- Adult-Use (Recreational) Cannabis Delivery & Online Ordering (CRANAGAH), Cannabis Online Ordering for Dispensary Pickup (Click-and-Collect) (CRANAGAC)
Keywords
Where Curaleaf is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
Curaleaf business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Retail dispensary sales: Direct-to-consumer cannabis product sales through 162–165 company-operated or branded dispensaries across 14+ U.S. states. Includes both medical marijuana and adult-use sales where legal, with separate regulatory tracking per state.
- Wholesale / B2B cannabis distribution: Wholesale distribution of cannabis flower, vapes, and processed products to third-party dispensaries and B2B customers, including branded products (Reef, Grassroots, Anthem, Select, Find, Dark Heart).
- International medical cannabis distribution: Distribution of EU-GMP certified medical cannabis and pharmaceutical-grade products in Germany (Four 20 Pharma), UK (Curaleaf Labs), Poland (Can4Med), Australia, and New Zealand. International Q4 2025 revenue of $51M (65% YoY growth).
- Cannabis cultivation and processing: Low-cost cultivation including outdoor grows (Los Sueños Farms — Colorado's largest outdoor cannabis farm), indoor grows, and processing for both company retail and wholesale channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Retail unit pricing for cannabis products at dispensaries |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels8 records
Curaleaf product offering
Product offeringCore offering
Curaleaf is a vertically integrated cannabis operator that cultivates, processes, manufactures, and sells medical and adult-use cannabis products. It operates company-owned retail dispensaries across 14+ U.S. states and distributes EU-GMP certified medical cannabis in Europe (Germany, UK, Poland), Canada, and Australasia, supported by a portfolio of proprietary consumer brands (Select, Grassroots, Find, Anthem, Reef, Dark Heart, Jams, Higher Stitch, Endless Coast, Zero Proof).
Differentiator
Problem solved
Functional benefit
Brands
- Select: Cannabis vape and concentrate brand; products include Select BRIQ vapes and the Select Briq 2 launched March 2026.
- Anthem
- Grassroots
- Find
- Reef
- Higher Stitch
- The Hemp Company
- Curaleaf Laboratories
- Zero Proof
- Dark Heart
Products and services
- Select cannabis vape and concentrate products
Quantifiable outcome
- Adjusted gross margin expanded to 49% in Q4 2025
- +5 more outcomes
Companies that use Curaleaf
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles5 records
Curaleaf technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
Feature4 records
Curaleaf partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered flagship — corporate restructuring, minor — event sponsorship, flagship — board of directors appointment, flagship — fully integrated subsidiary; cornerstone of european medical cannabis strategy, minor — partnership in restricted jurisdiction, core — uk influencer marketing agency of record, minor — sponsorship partner, major — $110m expansion deal, core — uk distribution partnership, core — strategic international expansion acquistion, core — polish market entry vehicle, minor — $20m retail acquisition, core — major u.s. retail acquisition ($211m), minor — $13m acquisition, major — $286m acquisition and major — $67m cultivation acquisition.
- Shareholders (Delaware reincorporation)flagship — corporate restructuringCuraleaf's 2026 annual and special shareholders meeting approved a plan of arrangement to reincorporate the company from British Columbia, Canada to Delaware, USA by 99.93% of votes cast, alongside other governance items. Expected to file articles amendment June 23, 2026.
- Avicanna (clinical symposium)minor — event sponsorshipCuraleaf sponsored Avicanna's sixth annual clinical symposium at the Mars Discovery District in Toronto, featuring academic and clinical sessions on cannabinoid research covering chronic pain, epilepsy, women's health, and brain injury.
- Torsten Greif (Four 20 Pharma co-founder)flagship — board of directors appointmentTorsten Greif, co-founder of Four 20 Pharma GmbH, was appointed to Curaleaf's Board of Directors in May 2026, bringing deep expertise in cannabis cultivation, regulatory strategy, and brand development to strengthen Curaleaf's European leadership team.
- Four 20 Pharma GmbH (Germany)flagship — fully integrated subsidiary; cornerstone of european medical cannabis strategyCuraleaf completed the buyout of the remaining 45% stake in Four 20 Pharma in April 2026, gaining full ownership. Originally acquired 55% stake in 2022 for €19.7M. Four 20 Pharma is a fully EU-GMP and GDP licensed German medical cannabis producer/distributor based in Paderborn with 110 employees. Co-founder Torsten Greif was appointed to Curaleaf's Board of Directors in May 2026.
- RC Retail (Ohio)minor — partnership in restricted jurisdictionCuraleaf-branded dispensary in Lorain, Ohio is operated by RC Retail, with Curaleaf providing support services while retaining future ownership rights subject to regulatory approval. Marks Curaleaf's 5th Ohio and 164th nationwide retail location.
- NewGen (creative agency)core — uk influencer marketing agency of recordNewGen was named agency of record for Curaleaf to lead its influencer marketing program for 2026, following a two-stage pitch process lasting four weeks. Partnership focuses on raising awareness of medical cannabis for treatment-resistant conditions and reducing associated stigma in the UK.
- Zig-Zag and Monster Energy (Art of Hip Hop exhibition sponsors)minor — sponsorship partnerCuraleaf was a sponsor alongside Zig-Zag and Monster Energy of the 'Heroes, Villains, and Violence' exhibition at The Art of Hip Hop space in Miami during Art Week, December 3-5, 2025.
- The Cannabist Company (Virginia assets)major — $110m expansion dealCuraleaf signed binding agreement to acquire The Cannabist Company's Virginia assets (cultivation facility and five dispensaries) for $110 million. Initially terminated in December 2025 due to valuation concerns ($130M competing bid plus $30M lease liability); later acquired the remaining Virginia assets of Cannabist for an undisclosed price.
- Australian Natural Therapeutics Group (ANTG)core — uk distribution partnershipCuraleaf Laboratories partnered with ANTG to manufacture and distribute ANTG's medicinal cannabis products across the UK. Combines Curaleaf's UK manufacturing and distribution network with ANTG's pharmaceutical-grade cannabis formulations. First ANTG products manufactured under the partnership became available on prescription in November 2025.
- Northern Green Canada (NGC)core — strategic international expansion acquistionCuraleaf completed the acquisition of NGC (a Canadian licensed producer with EU-GMP certification) for approximately $16 million including earnout in April 2024. NGC enhances Curaleaf's supply of EU-GMP certified cannabis for European, Australian, and New Zealand markets — Germany, the UK, Poland, Australia, and New Zealand.
- Can4Med (Poland)core — polish market entry vehicleCuraleaf International acquired Can4Med, a pharmaceutical wholesaler specializing in cannabinoid medications in Poland. The acquisition positions Curaleaf in Poland's expanding medical cannabis market, with rapidly growing patient population.
- Deseret Wellness (Utah)minor — $20m retail acquisitionCuraleaf completed acquisition of Deseret Wellness, Utah's largest cannabis retail operator, in a deal valued at approximately $20 million. Increased Curaleaf's Utah retail footprint and expanded overall nationwide presence.
- Bloom Dispensaries (Arizona)core — major u.s. retail acquisition ($211m)Curaleaf acquired Bloom Dispensaries in an all-cash transaction valued at approximately $211 million. Expanded Curaleaf's Arizona dispensary presence to 13 locations and overall U.S. dispensary count to 121 locations nationwide. Bloom's strong financial profile was immediately accretive to Curaleaf's EBITDA margins.
- Natural Remedy Patient Center (Arizona)minor — $13m acquisitionCuraleaf agreed to acquire Natural Remedy Patient Center in Arizona for $13 million, expanding Curaleaf's Arizona dispensary footprint with plans to relocate to a flagship Scottsdale location in mid-2022.
- Tryke Companies (Reef Dispensaries)major — $286m acquisitionCuraleaf agreed to acquire Tryke Companies for approximately $286 million in cash and shares, strengthening market position in Nevada, Arizona, and Utah. Tryke operated six Reef dispensaries across Arizona and Nevada.
- Los Sueños Farms (Colorado)major — $67m cultivation acquisitionCuraleaf acquired Los Sueños Farms, Colorado's largest outdoor cannabis farm, for $67 million in cash, stock, and debt assumption. Includes three outdoor grow facilities, an indoor grow, and two retail dispensaries. Supports low-cost supply chain and interstate commerce preparation.
Scale indicators10 records
Recent moves8 records
Expansion highlights7 records
Curaleaf competitors and assessment
Company assessmentDirect peers
- Trulieve Cannabis: Direct multi-state operator (MSO) peer. Trulieve is the other top U.S. MSO by retail footprint and is explicitly mentioned alongside Curaleaf in BNN Bloomberg's Hot Pick list and the 2026 Cannabis AI Visibility Index, where Curaleaf and Trulieve together captured ~17.5% of AI citations.
- Verano Holdings: Direct U.S. MSO peer identified alongside Curaleaf in Canaccord/BNN Bloomberg's Hot Picks amid rescheduling momentum. Operates a comparable vertically integrated retail and cultivation model across multiple states.
- Green Thumb Industries: U.S. MSO peer operating a vertically integrated retail and cultivation platform across multiple states. Closely comparable business model and footprint strategy to Curaleaf.
- Cresco Labs: U.S. MSO peer with comparable multi-state retail and wholesale operations and a focus on branded products. Direct competitor in the wholesale channel where Curaleaf sells Select, Grassroots, and other brands.
- Tilray Brands: Major cannabis operator with both U.S. MSO operations and significant international (Canadian, European, Australian) footprint, making it a direct peer on both U.S. retail and international medical cannabis distribution — Curaleaf's stated growth pillars.
- The Cannabist Company: U.S. MSO peer. Curaleaf signed then terminated a $110M binding agreement to acquire Cannabist's Virginia assets in December 2025 after a competing bid, establishing Cannabist as a comparable U.S. retail and cultivation operator.
Broad incumbents
- Aurora Cannabis: Canadian licensed producer with significant European medical cannabis presence through Aurora Deutschland. Comparable to Curaleaf's NGC and Four 20 Pharma infrastructure as a competitor in the EU-GMP medical cannabis supply chain.
- Canopy Growth: Broad incumbent with both Canadian recreational operations and European medical cannabis business. Comparable as a global cannabis operator with established international distribution competing for European patient share.
Emerging players
- OrganiGram Holdings: Canadian licensed producer expanding into European medical cannabis markets. Comparable as a competitor for EU-GMP certified supply into Germany and UK, though smaller scale than Curaleaf's NGC/Four 20 Pharma platform.
Regional players
- Schwazze: U.S. vertically integrated cannabis operator primarily concentrated in Colorado and New Mexico with a growing multi-state footprint. Comparable vertically integrated model and overlap in Colorado retail/cultivation with Curaleaf's Los Sueños Farms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Curaleaf social profiles
Digital presenceCuraleaf financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curaleaf leadership team
Management profileNumber of profiles
Profiles3 records
Curaleaf subsidiaries and ownership
Company hierarchySubsidiaries9 records
Curaleaf funding detail
Funding detailFunding overview
Funding rounds14 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curaleaf M&A and investment
M&A and investmentM&A13 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curaleaf
What does Curaleaf do?
Curaleaf is a vertically integrated cannabis operator that cultivates, processes, manufactures, and sells medical and adult-use cannabis products. It operates company-owned retail dispensaries across 14+ U.S. states and distributes EU-GMP certified medical cannabis in Europe (Germany, UK, Poland), Canada, and Australasia, supported by a portfolio of proprietary consumer brands (Select, Grassroots, Find, Anthem, Reef, Dark Heart, Jams, Higher Stitch, Endless Coast, Zero Proof).
Is Curaleaf a public or private company?
Curaleaf is a public company. It is classified as public and is currently operating.
When was Curaleaf founded?
Curaleaf was founded in 2010. It employs 1,001 to 5,000 people.
Where is Curaleaf based?
Curaleaf is headquartered in Stamford, United States, in the North America region.
How does Curaleaf make money?
Four revenue lines are on record. Retail dispensary sales are the primary driver. The others are wholesale / B2B cannabis distribution, international medical cannabis distribution and cannabis cultivation and processing.
Who are Curaleaf's main competitors?
Direct peers on record are Trulieve Cannabis, Verano Holdings, Green Thumb Industries, Cresco Labs, Tilray Brands and The Cannabist Company. Broad incumbents are Aurora Cannabis and Canopy Growth. OrganiGram Holdings is listed as an emerging player. Schwazze is listed as a regional player.
Does Curaleaf have an API?
No public API is recorded for Curaleaf.
What industry is Curaleaf in?
Curaleaf's product category is Cannabis Products. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAGAH, Adult-Use (Recreational) Cannabis Delivery & Online Ordering. Its NAICS code is 445320.